WO2004108141A3 - Bach-o-protein coupled receptor releated methods - Google Patents

Bach-o-protein coupled receptor releated methods Download PDF

Info

Publication number
WO2004108141A3
WO2004108141A3 PCT/GB2004/002301 GB2004002301W WO2004108141A3 WO 2004108141 A3 WO2004108141 A3 WO 2004108141A3 GB 2004002301 W GB2004002301 W GB 2004002301W WO 2004108141 A3 WO2004108141 A3 WO 2004108141A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpcr
adp
pain
bach
migraine
Prior art date
Application number
PCT/GB2004/002301
Other languages
French (fr)
Other versions
WO2004108141A2 (en
Inventor
Samuel Aparicio
Original Assignee
Paradigm Therapeutics Ltd
Samuel Aparicio
Ellery Jonathan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paradigm Therapeutics Ltd, Samuel Aparicio, Ellery Jonathan filed Critical Paradigm Therapeutics Ltd
Publication of WO2004108141A2 publication Critical patent/WO2004108141A2/en
Publication of WO2004108141A3 publication Critical patent/WO2004108141A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

We disclose that ADP is capable of binding to and activating the BACH-Gprotein coupled receptor (BACCH-GPCR). We describe methods of identifying a compound or an agent which is capable of modulating the ability of ADP to activate the BACK-GPCR. We also describe using ADP or derivatives thereof or modulators of the binding between ADP and the BACK-GPCR for treating diseases associated with BACH-GPCR consisting of trigeminal neuralgia, pain of various origins, irritable bowel syndrome, bladder instability, Barrett’s esophagus, glaucoma, pain associated with cancer, diabetic neuropathies, Herpes virus infections, migraine and skin sensitivity associated with migraine, allodynia, toothache, neuroma, dementia, dyslexia, dyskinesias, tremor, Parkinson’s, benign essential tremor, chorea, epilepsy or ballismus, for example occurring through stroke, trauma, degeneration and malignancy, chronic pain (peripheral or visceral) and relapsing remitting pain such as migraine, dry eye disorder, cyctic fibrosis, hyperactive bladder, hypercholesterolaemia, dislipdaemias and obesity.
PCT/GB2004/002301 2003-06-04 2004-06-01 Bach-o-protein coupled receptor releated methods WO2004108141A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312844,4 2003-06-04
GBGB0312844.4A GB0312844D0 (en) 2003-06-04 2003-06-04 Use of compounds in medicine

Publications (2)

Publication Number Publication Date
WO2004108141A2 WO2004108141A2 (en) 2004-12-16
WO2004108141A3 true WO2004108141A3 (en) 2005-03-31

Family

ID=9959315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002301 WO2004108141A2 (en) 2003-06-04 2004-06-01 Bach-o-protein coupled receptor releated methods

Country Status (2)

Country Link
GB (1) GB0312844D0 (en)
WO (1) WO2004108141A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018275A1 (en) 2007-07-30 2009-02-05 University Of Rochester Adenosine and its mimetics, modulators, transport inhibitors, and receptor agonists as a therapeutic tool to replace or improve the efficacy of deep brain stimulation
ITTO20110576A1 (en) * 2011-06-30 2012-12-31 Medicam Health Science S R L COMPOSITION INCLUDING THE ASSOCIATION OF MELISSA PHYTO-EXTRACT, METHYLAMIDE AND A SOURCE OF NUCLEOTIDES AND / OR NUCLEOSIDES AND ITS USE IN THE TREATMENT OF HEADACHE AND HEMICRYANES
WO2019204392A1 (en) * 2018-04-17 2019-10-24 Purdue Research Foundation Modifying surface of a live cell and the uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547942A (en) * 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
WO2001043733A2 (en) * 1999-12-15 2001-06-21 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
WO2001045691A2 (en) * 1999-12-22 2001-06-28 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
WO2002038607A2 (en) * 2000-11-07 2002-05-16 Paradigm Therapeutics Limited A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
WO2003014731A2 (en) * 2001-08-07 2003-02-20 Euroscreen S.A. The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
US20030059857A1 (en) * 2001-09-17 2003-03-27 Schering Corporation G-protein coupled receptor and methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547942A (en) * 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
WO2001043733A2 (en) * 1999-12-15 2001-06-21 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
WO2001045691A2 (en) * 1999-12-22 2001-06-28 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
WO2002038607A2 (en) * 2000-11-07 2002-05-16 Paradigm Therapeutics Limited A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
WO2003014731A2 (en) * 2001-08-07 2003-02-20 Euroscreen S.A. The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
US20030059857A1 (en) * 2001-09-17 2003-03-27 Schering Corporation G-protein coupled receptor and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DOL-GLEIZES F ET AL: "Relaxant effect of 2-methyl-thio-adenosine diphosphate on rat thoracic aorta: effect of clopidogrel.", EUROPEAN JOURNAL OF PHARMACOLOGY. 19 FEB 1999, vol. 367, no. 2-3, 19 February 1999 (1999-02-19), pages 247 - 253, XP001202603, ISSN: 0014-2999 *
OGATA TADANORI ET AL: "Adenosine triphosphate inhibits cytokine release from lipopolysaccharide-activated microglia via P2y receptors.", BRAIN RESEARCH. 15 AUG 2003, vol. 981, no. 1-2, 15 August 2003 (2003-08-15), pages 174 - 183, XP001202601, ISSN: 0006-8993 *

Also Published As

Publication number Publication date
WO2004108141A2 (en) 2004-12-16
GB0312844D0 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
WO2007021647A3 (en) Method for treating myocradial rupture
FI3687999T3 (en) Rapamycin derivatives
CA2514539A1 (en) Process for producing coated preparation
BRPI0518173A8 (en) ophthalmic compositions
WO2004108141A3 (en) Bach-o-protein coupled receptor releated methods
WO2006047466A3 (en) Ophthamological drugs
WO2007047607A3 (en) Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
WO2005046572A3 (en) Targeted delivery of controlled release polymer systems
WO2005030254A3 (en) Conjugates for photodynamic therapy
WO2007070819A3 (en) Spinous process fixation implant
WO2003066851A3 (en) Irreversible immobilization of diisopropylfluorophophatase into polyurethane coatings
JP2008543776A5 (en)
WO2007028821A3 (en) Treatment of autoimmune diseases
WO2006135873A3 (en) Parp modulators and treatment of cancer
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
Tishchenko et al. Low-molecular-weight chitosans: Preparation and characterization
Findlay et al. Human saccadic eye movements
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2007028347A3 (en) Method for the preparation of polymeric conjugates of doxorubicin with ph- controlled release of the drug
WO2007067737A3 (en) Methods and compositions for inhibiting hiv infection
WO2007137236A3 (en) Drug loaded contrast agents: combining diagnosis and therapy
WO2005026268A3 (en) Branched polymers and coating compositions made therefrom
WO2007002131A3 (en) Galk1s as modifiers of the pten/akt pathway and methods of use
WO2007081359A3 (en) Protective aqueous treatment for wood and method for producing treatment
JP2017519570A (en) Needleless injection device with fixed double membrane

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase